Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Prism Biolab Co., Ltd. (206A:JPX), powered by AI.
Prism Biolab Co., Ltd. is currently trading at ¥135. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Prism Biolab Co., Ltd. on Alpha Lenz.
View Prism Biolab Co., Ltd.'s valuation metrics on Alpha Lenz.
“Prism Biolab Co., Ltd.'s ROE is -26.8%. Explore profitability and growth together.”
Ask for details →Prism Biolab Co., Ltd. is a pioneering biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Specializing in regenerative medicine and pharmaceutical research, the company aims to address unmet medical needs through cutting-edge biotechnology. Prism Biolab's notable work includes the development of proprietary compounds and technologies that contribute to advancements in tissue engineering and biologics. The firm is heavily engaged with sectors such as healthcare and pharmaceuticals, serving a broad spectrum of clients that range from hospitals to academic research institutions. Prism Biolab Co., Ltd. is significant in the financial market as it represents the intersection of medical innovation and investment opportunities. The company's work not only fosters potential breakthroughs in treatment methodologies but also drives growth within the biotech industry, underlining its critical role in advancing healthcare technologies worldwide.
“Prism Biolab Co., Ltd.'s ROE is -26.8%. Explore profitability and growth together.”
Ask for details →Prism Biolab Co., Ltd. (ticker: 206A) is a company listed on JPX in the Healthcare sector (Biotechnology).
The current price is 135 with a P/E ratio of -x and P/B of -x.
ROE is -26.84% and operating margin is -114.34%. Annual revenue is $677M.